Treatment Protocol of the First International Study of Langerhans Cell Histiocytosis in adults
Phase 2
- Conditions
- Langerhans Cell HistiocytosisLCH1004795410018865
- Registration Number
- NL-OMON30781
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
- definitive diagnosis of LCH
- no prior cytoreductive treatment for LCH
Exclusion Criteria
- patients with severe impairment of clinical condition including severely impaired pulmonary function, long term oxygen therapy or cor pulmonale.
- treatment with immune suppressive agents and/or biphosphonates within 4 weeks from baseline evaluation
- pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>definition and implementation of an uniform treatment for patients with single<br /><br>system LCH, multisystem LCH and pulmonary isolated LCH, implementation of<br /><br>uniform initial evaluation and stratification criteria.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable.</p><br>